Cancer Chemotherapy and Pharmacology

, Volume 56, Issue 5, pp 487–491

Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study

  • G. P. Stathopoulos
  • D. Tsavdaridis
  • N. A. Malamos
  • S. K. Rigatos
  • Ch. Kosmas
  • N. Pergantas
  • J. G. Stathopoulos
  • J. Xynotroulas
Original Article

DOI: 10.1007/s00280-005-1006-3

Cite this article as:
Stathopoulos, G.P., Tsavdaridis, D., Malamos, N.A. et al. Cancer Chemother Pharmacol (2005) 56: 487. doi:10.1007/s00280-005-1006-3

Abstract

Purpose: This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively. Methods: Forty-eight (median age 54 years, range 26–77 year) patients, all evaluable, were enrolled. All patients had been pre-treated with anthracycline-combined chemotherapy, 30 of whom were also treated with paclitaxel and 2 with docetaxel. World Health Organization (WHO) performance status was 0–2. The dominant metastasis was in the liver (54.17%), in the lungs (27.08%), in soft tissues (12.50%) and in the skeleton (6.25%). Treatment involved irinotecan infusion 200 mg/m2 for 90 min and docetaxel infusion 80 mg/m2 for 90 min, repeated once every 3 weeks. Results: Twenty-five (52.08%, 95% confidence interval [CI] 37.95–66.21) patients showed responses: 3 complete (6.25%, 95% CI 0–13.05) and 22 (45.83%, 95% CI 31.74–59.92) partial; the most responsive metastases were observed at the liver site (53.85%). Grade 3 and 4 neutropenia was observed in 18 patients (37.50%); 14 (29.17%) patients developed anaemia and three (6.25%), thrombocytopenia. Concerning non-haematologic toxicity, alopecia and fatigue were common; grade 3 diarrhea was observed in only one (2.08%) patient. Conclusion: The irinotecan-docetaxel combination produces quite a high response rate in pre-treated advanced breast cancer patients.

Keywords

Irinotecan Docetaxel Breast cancer 

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • G. P. Stathopoulos
    • 1
  • D. Tsavdaridis
    • 2
  • N. A. Malamos
    • 3
  • S. K. Rigatos
    • 1
  • Ch. Kosmas
    • 4
  • N. Pergantas
    • 5
  • J. G. Stathopoulos
    • 1
  • J. Xynotroulas
    • 1
  1. 1.First Oncology DepartmentErrikos Dunant HospitalAthensGreece
  2. 2.Oncology UnitIKAThessalonikiGreece
  3. 3.Oncology UnitHelena HospitalAthensGreece
  4. 4.Metaxa HospitalPiraeusGreece
  5. 5.Oncology UnitIKAAthensGreece

Personalised recommendations